Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents

Background: Decitabine and cedazuridine (DEC-C) is the only oral hypomethylating agent (HMA) approved for myelodysplastic syndromes (MDS) in the United States. The other HMAs approved for MDS, decitabine and azacitidine, are administered intravenously (IV) or subcutaneously (SC). Objectives: This st...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Amer M. Zeidan, Ruizhi Zhao, Jon G. Tepsick, Ziyu Lan, Tehseen Salimi
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	SAGE Publishing 2026-02-01
Seri Bilgileri:	Therapeutic Advances in Hematology
Online Erişim:	https://doi.org/10.1177/20406207261421326
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!